Lukas Rindlisbacher joined Nextech Invest Ltd. as an intern in 2018 and later transitioned to an analyst in 2019. In 2020, Lukas began his PhD studies at the University of Zurich and supports Nextech as a Fellow. Lukas is excited to be working where science meets business and strategy, and to help companies bring the next generation of medicines to the people in need. At Nextech, Lukas focuses on scientific due diligence for investment opportunities and company build activities. He holds a B.S. in molecular biology and an M.Sc. in molecular health sciences from the Swiss Federal Institute of Technology Zürich (ETH), where he conducted translational research with Professor Dario Neri on novel bispecific antibody formats.
Lukas spends most of his free time in the Alps hiking or skiing and being in touch with nature, fitting right into the Swiss stereotype.